Automatic Website Traffic RSS

Alvotech signs U.S. agreement to expand access for high-concentration interchangeable Humira biosimilar

Alvotech announced a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly Food and Drug Administration approved high-concentration ... read more

Loss of Anti-TNF Treatment Response Common in Crohn's Disease

Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based ... read more

With CVS cost-cutting move, AbbVie's Humira dam begins to crack

AbbVie’s blockbuster drug managed to hang on to most of its market in the first year it faced biosimilar competition, but the tide appears to be turning. read more

Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.

Alvotech (NASDAQ:ALVO) in agreement with Teva Pharmaceuticals (NYSE:TEVA), signed a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the ... read more

What Clinicians Need to Know About Using Biosimilars to Treat IBD

A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are ... read more

Safe Adalimumab Therapy for Rheumatoid Arthritis in a Patient With Pre-existing Multiple Myeloma

One important group of biologics encompasses substances that block the actions of TNF. Adalimumab, an entirely human-derived recombinant monoclonal antibody specific to TNF, is effective for the ... read more

Humira (adalimumab) and cost

Humira (adalimumab) is a brand-name subcutaneous injection that’s prescribed for certain conditions, such as rheumatoid arthritis. The cost of the drug with and without insurance can depend on ... read more

Alvotech moves to bring its Humira biosimilar to US market

The long-term agreement will see increased access of Simlandi, a biosimilar to AbbVie’s Humira, in the US market. read more

AbbVie Plays Its Ace Cards Against Humira’s Decline

Ten biosimilars to Humira are now on the market, but AbbVie’s Skyrizi and Rinvoq are soaking up revenues as Humira’s sales fall off. read more

Efficacy and Safety of Infliximab or Adalimumab, Versus Abatacept, in Patients With Rheumatoid Arthritis

Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of ... read more

Disseminated coccidioidomycosis in a patient managed with adalimumab for Crohn's disease

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease. read more

Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

Good morning and good afternoon, and welcome to the Novartis Q1 2024 results release conference call and live webcast. [Operator instructions] The conference is being recorded. [Operator instructions] ... read more